Dan Ives, Wedbush Securities global head of technology research and senior equity analyst, joins 'Squawk Box' to discuss ...

Research analysts at Wedbush issued their FY2029 EPS estimates for shares of Arcus Biosciences in a note issued to investors ...

Equities researchers at Wedbush lifted their Q4 2025 earnings per share estimates for shares of CarMax in a research note ...

In a report released today, Yun Zhong from Wedbush maintained a Buy rating on BioMarin Pharmaceutical (BMRN – Research Report), with a price ...

Dan Ives, Wedbush Securities global head of technology research, joins CNBC's 'Squawk on the Street' to break down ...

Dan Ives, Managing Director and Senior Equity Analyst at Wedbush Securities, shares his expert insights on the future of AI, ...

Wedbush made a splash on Tuesday with the announcement that it was entering the ever-growing ETF market. Read more here.

Wedbush analyst Robert Driscoll last night initiated coverage of Avalo Therapeutics (AVTX) with an Outperform rating and $18 price target ...

Palantir Technologies received a new Buy rating from Loop Capital and continued bullish support from Wedbush on Thursday, despite recent market concerns over potential U.S. defense budget cuts.

Wedbush Securities, a leading financial services and investment firm, is proud to announce the launch of fast and efficient services for easy-to-borrow, locates and hard-to-borrow securities.

AI spending is ramping up, with Nvidia (NVDA) seeing strong Blackwell demand and IT budgets shifting toward AI investments ...

Investing.com -- Tesla's stock has faced continued pressure in 2025, but Wedbush analysts remain bullish, maintaining their ...